1
|
Olivares-Hernández A, del Barco Morillo E, Miramontes-González JP, Figuero-Pérez L, Pérez-Belmonte L, Martín-Vallejo J, Martín-Gómez T, Escala-Cornejo R, Vidal-Tocino R, Hernández LB, Sarmiento RG, Ludeña de la Cruz MD, Cruz-Hernández JJ, Pérez CP. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy. Front Biosci (Landmark Ed) 2022; 27:88. [DOI: 10.31083/j.fbl2703088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Revised: 02/14/2022] [Accepted: 02/15/2022] [Indexed: 11/06/2022]
|
2
|
Olivares-Hernández A, del Barco Morillo E, Parra Pérez C, Miramontes-González JP, Figuero-Pérez L, Martín-Gómez T, Escala-Cornejo R, Bellido Hernández L, González Sarmiento R, Cruz-Hernández JJ, Ludeña de la Cruz MD. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. Biomedicines 2022; 10:biomedicines10020360. [PMID: 35203569 PMCID: PMC8962390 DOI: 10.3390/biomedicines10020360] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 01/23/2022] [Accepted: 01/27/2022] [Indexed: 01/01/2023] Open
Abstract
Mutations in the mismatch repair (MMR) system predict the response to immune checkpoint inhibitors (ICIs) like colon or gastric cancer. However, the MMR system’s involvement in non-small cell lung cancer (NSCLC) remains unknown. Addressing this issue will improve clinical guidelines in the case of mutations in the main genes of the MMR system (MLH1, MSH2, MSH6, and PMS2). This work retrospectively assessed the role that these gene mutations play in the response to and survival of ICIs in NSCLC. Patients with NSCLC treated with nivolumab as the second-line treatment in the University Hospital of Salamanca were enrolled in this study. Survival and response analyses were performed according to groups of MMR system gene expression (MMR expression present or deficiency) and other subgroups, such as toxicity. There was a statistically significant relationship between the best response obtained and the expression of the MMR system (p = 0.045). The presence of toxicity grade ≥ 3 was associated with the deficiency expression of MMR (dMMR/MSI-H) group (p = 0.022; odds ratio = 10.167, 95% confidence interval (CI) 1.669–61.919). A trend towards greater survival and response to ICIs was observed in NSCLC and dMMR. Assessing the genes in the MMR system involved in NSCLC is key to obtaining personalized immunotherapy treatments.
Collapse
Affiliation(s)
- Alejandro Olivares-Hernández
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (E.d.B.M.); (L.F.-P.); (T.M.-G.); (L.B.H.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Correspondence: (A.O.-H.); (C.P.P.); Tel.: +34-923-29-11-00 (A.O.-H. & C.P.P.); Fax: +34-923-29-13-25 (A.O.-H. & C.P.P.)
| | - Edel del Barco Morillo
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (E.d.B.M.); (L.F.-P.); (T.M.-G.); (L.B.H.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Department of Medicine, University of Salamanca, 37007 Salamanca, Spain;
| | - Carmen Parra Pérez
- Department of Medicine, University of Salamanca, 37007 Salamanca, Spain;
- Department of Pathology, University Hospital of Salamanca, 37007 Salamanca, Spain
- Correspondence: (A.O.-H.); (C.P.P.); Tel.: +34-923-29-11-00 (A.O.-H. & C.P.P.); Fax: +34-923-29-13-25 (A.O.-H. & C.P.P.)
| | - José Pablo Miramontes-González
- Department of Internal Medicine, University Hospital Rio Hortega, 47012 Valladolid, Spain;
- Department of Medicine, University of Valladolid, 45005 Valladolid, Spain
| | - Luis Figuero-Pérez
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (E.d.B.M.); (L.F.-P.); (T.M.-G.); (L.B.H.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
| | - Teresa Martín-Gómez
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (E.d.B.M.); (L.F.-P.); (T.M.-G.); (L.B.H.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Department of Medicine, University of Salamanca, 37007 Salamanca, Spain;
| | | | - Lorena Bellido Hernández
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (E.d.B.M.); (L.F.-P.); (T.M.-G.); (L.B.H.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
| | - Rogelio González Sarmiento
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Department of Medicine, University of Salamanca, 37007 Salamanca, Spain;
| | - Juan Jesús Cruz-Hernández
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (E.d.B.M.); (L.F.-P.); (T.M.-G.); (L.B.H.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Department of Medicine, University of Salamanca, 37007 Salamanca, Spain;
| | - María Dolores Ludeña de la Cruz
- Department of Medicine, University of Salamanca, 37007 Salamanca, Spain;
- Department of Pathology, University Hospital of Salamanca, 37007 Salamanca, Spain
| |
Collapse
|
3
|
Muro A, Belhassen-García M, Muñoz Bellido JL, Lorenzo Juanes H, Vicente B, Pendones J, Adserias J, Sánchez Hernández G, Rodríguez Rosa M, Vicente Villardón JL, Burguillo J, López Andaluz J, Martín Oterino JA, García Criado FJ, Barbero F, Morales AI, Galindo Villardón P, González Sarmiento R. Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study. J Clin Med 2021; 10:3214. [PMID: 34361998 PMCID: PMC8348112 DOI: 10.3390/jcm10153214] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 07/10/2021] [Accepted: 07/15/2021] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called "DIANCUSAL" (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial. OBJECTIVE The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity. METHODOLOGY The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July-October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM. PRINCIPAL FINDINGS A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties (p = 0.006). Based on the questionnaire, loss of smell and fever were the symptoms most strongly associated with seropositivity, and 22.6% of seropositive participants were asymptomatic. Social distancing was the most effective hygiene measure (p = 0.0007). There were significant differences in seroprevalence between participants with and without household exposure to SARS-CoV-2 (p = 0.0000), but not between students who lived in private homes and those who lived in dormitories. IgG antibodies decreased over time in the participants with confirmed self-reported COVID-19 diagnoses. CONCLUSIONS The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures.
Collapse
Affiliation(s)
- Antonio Muro
- Infectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain;
| | - Moncef Belhassen-García
- Infectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain;
| | - Juan Luís Muñoz Bellido
- Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain; (J.L.M.B.); (H.L.J.); (J.P.); (J.A.M.O.); (F.J.G.C.); (A.I.M.); (R.G.S.)
- Microbiology & Parasitology Service, University Hospital of Salamanca, 37007 Salamanca, Spain
- Department of Biomedical and Diagnostic Sciences, University of Salamanca, 37008 Salamanca, Spain
| | - Helena Lorenzo Juanes
- Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain; (J.L.M.B.); (H.L.J.); (J.P.); (J.A.M.O.); (F.J.G.C.); (A.I.M.); (R.G.S.)
- Microbiology & Parasitology Service, University Hospital of Salamanca, 37007 Salamanca, Spain
- Department of Biomedical and Diagnostic Sciences, University of Salamanca, 37008 Salamanca, Spain
| | - Belén Vicente
- Infectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain;
| | - Josué Pendones
- Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain; (J.L.M.B.); (H.L.J.); (J.P.); (J.A.M.O.); (F.J.G.C.); (A.I.M.); (R.G.S.)
- Microbiology & Parasitology Service, University Hospital of Salamanca, 37007 Salamanca, Spain
- Department of Biomedical and Diagnostic Sciences, University of Salamanca, 37008 Salamanca, Spain
| | - José Adserias
- IT Department, University of Salamanca Foundation (FGUSAL), University of Salamanca, 37008 Salamanca, Spain;
| | | | - Miguel Rodríguez Rosa
- Department of Statistics, University of Salamanca, 37008 Salamanca, Spain; (M.R.R.); (J.L.V.V.); (P.G.V.)
| | | | - Javier Burguillo
- Department of Chemistry-Physics, Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, Spain;
| | - Javier López Andaluz
- Department of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, Spain; (J.L.A.); (F.B.)
| | - Jose Angel Martín Oterino
- Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain; (J.L.M.B.); (H.L.J.); (J.P.); (J.A.M.O.); (F.J.G.C.); (A.I.M.); (R.G.S.)
- Department of Internal Medicine, Faculty of Medicine, University Hospital of Salamanca, 37008 Salamanca, Spain
| | - Francisco Javier García Criado
- Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain; (J.L.M.B.); (H.L.J.); (J.P.); (J.A.M.O.); (F.J.G.C.); (A.I.M.); (R.G.S.)
| | - Fausto Barbero
- Department of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, Spain; (J.L.A.); (F.B.)
| | - Ana Isabel Morales
- Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain; (J.L.M.B.); (H.L.J.); (J.P.); (J.A.M.O.); (F.J.G.C.); (A.I.M.); (R.G.S.)
- Toxicology Unit, University of Salamanca, 37008 Salamanca, Spain
| | | | - Rogelio González Sarmiento
- Institute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, Spain; (J.L.M.B.); (H.L.J.); (J.P.); (J.A.M.O.); (F.J.G.C.); (A.I.M.); (R.G.S.)
- Molecular Medicine Unit, Department of Medicine, University of Salamanca, 37008 Salamanca, Spain
| | | |
Collapse
|
4
|
Olivares-Hernández A, Figuero-Pérez L, Terán-Brage E, López-Gutiérrez Á, Velasco ÁT, Sarmiento RG, Cruz-Hernández JJ, Miramontes-González JP. Resistance to Immune Checkpoint Inhibitors Secondary to Myeloid-Derived Suppressor Cells: A New Therapeutic Targeting of Haematological Malignancies. J Clin Med 2021; 10:jcm10091919. [PMID: 33925214 PMCID: PMC8124332 DOI: 10.3390/jcm10091919] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Revised: 04/17/2021] [Accepted: 04/23/2021] [Indexed: 01/11/2023] Open
Abstract
Myeloid-derived suppressor cells (MDSCs) are a set of immature myeloid lineage cells that include macrophages, granulocytes, and dendritic cell precursors. This subpopulation has been described in relation to the tumour processes at different levels, including resistance to immunotherapy, such as immune checkpoint inhibitors (ICIs). Currently, multiple studies at the preclinical and clinical levels seek to use this cell population for the treatment of different haematological neoplasms, together with ICIs. This review addresses the different points in ongoing studies of MDSCs and ICIs in haematological malignancies and their future significance in routine clinical practice.
Collapse
Affiliation(s)
- Alejandro Olivares-Hernández
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (L.F.-P.); (E.T.-B.); (Á.L.-G.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Correspondence: (A.O.-H.); (J.P.M.-G.); Tel.: +34-923-29-11-00 (A.O.-H.); +34-983-42-04-00 (J.P.M.-G.); Fax: +34-923-29-13-25 (A.O.-H.); +34-983-21-53-65 (J.P.M.-G.)
| | - Luis Figuero-Pérez
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (L.F.-P.); (E.T.-B.); (Á.L.-G.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
| | - Eduardo Terán-Brage
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (L.F.-P.); (E.T.-B.); (Á.L.-G.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
| | - Álvaro López-Gutiérrez
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (L.F.-P.); (E.T.-B.); (Á.L.-G.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
| | - Álvaro Tamayo Velasco
- Department of Haematology, University Hospital of Valladolid, 47003 Valladolid, Spain;
| | - Rogelio González Sarmiento
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Department of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - Juan Jesús Cruz-Hernández
- Department of Medical Oncology, University Hospital of Salamanca, 37007 Salamanca, Spain; (L.F.-P.); (E.T.-B.); (Á.L.-G.); (J.J.C.-H.)
- Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain;
- Department of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - José Pablo Miramontes-González
- Department of Internal Medicine, University Hospital Rio Hortega, 47012 Valladolid, Spain
- Department of Medicine, University of Valladolid, 45005 Valladolid, Spain
- Correspondence: (A.O.-H.); (J.P.M.-G.); Tel.: +34-923-29-11-00 (A.O.-H.); +34-983-42-04-00 (J.P.M.-G.); Fax: +34-923-29-13-25 (A.O.-H.); +34-983-21-53-65 (J.P.M.-G.)
| |
Collapse
|
5
|
Olivares Hernández AJ, Escala Cornejo RA, Figuero Pérez L, Vidal R, Escalera Martín E, Claros Ampuero J, Casado Elía D, García Muñoz M, Amores Martin A, Rodriguez CA, González Sarmiento R, Miramontes González JP, Cruz-Hernández JJ. Use of glycosylated hemoglobin and C-peptide levels in the diagnosis and prevention of type 1 diabetes mellitus as an immune-related adverse event secondary to treatment with immunotherapy in solid tumors. J Clin Oncol 2020. [DOI: 10.1200/jco.2020.38.5_suppl.97] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
97 Background: Type 1 diabetes mellitus (T1D) as an immune-related adverse event (irAE) is found in 0.5-5% of all patients treated with immunotherapy (IT) and it is associated with life-threatening complications. However, there are no official guidelines that suggest methods for the prevention and monitoring of T1D during treatment with IT. The algorithms described in the literature only assess the fasting blood sugar levels for prevention and monitoring. The objective of this review is to find factors that establish a relationship with the appearance of T1D as an irAE and to put forward a new algorithm for prevention and monitoring based on those findings. Methods: We carried out a clinical review of the cases published in the literature on T1D secondary to IT between 2012 and 2019. Through a statistical analysis, the relevant clinical characteristics will be determined, together with the factors related to the appearance of T1D, which will make it possible to put forward a new algorithm for the prevention and monitoring of T1D during treatment with IT for solid tumors. Results: Eighty one cases were reported. Of the reported cases, 90% were associated with Nivolumab or Pembrolizumab. The median age was 67 years (23-84 years), and the patients were predominantly men. The average number of administered doses was 5.3 with a lapse of 14.6 weeks from the administration of the first dose until diagnosis. In 48 cases (59%) the levels of C-peptide were low or undetectable, and the glycosylated hemoglobin (HbA1c) levels were elevated by an average of 8.8% (73 mmol/mol). Anti-β-cell antibodies were found in less than half of the patients (44). Diabetic ketoacidosis was observed at diagnosis in 61 patients (75%). Conclusions: Based on the results of our review, we propose including the levels of C-peptide and HbA1C in the usual protocol for the management of adverse events related to IT. Our algorithm suggests that the levels must be determined prior to the IT, after the first 2 cycles, and then every 2 months. This algorithm will enable the prevention, early diagnosis and monitoring of T1D during treatment with IT.
Collapse
Affiliation(s)
| | | | - Luis Figuero Pérez
- Department of Medical Oncology. Salamanca University Healthcare Complex., Salamanca, Spain
| | - Rosario Vidal
- Department of Medical Oncology. Salamanca University Healthcare Complex., Salamanca, Spain
| | - Elena Escalera Martín
- Department of Medical Oncology. Salamanca University Healthcare Complex., Salamanca, Spain
| | - Juncal Claros Ampuero
- Department of Medical Oncology. Salamanca University Healthcare Complex., Salamanca, Spain
| | - Diego Casado Elía
- Department of Medical Oncology. Salamanca University Healthcare Complex., Salamanca, Spain
| | - María García Muñoz
- Department of Medical Oncology. Salamanca University Healthcare Complex., Salamanca, Spain
| | | | | | | | | | - Juan J. Cruz-Hernández
- Department of Medical Oncology. Salamanca University Healthcare Complex., Salamanca, Spain
| |
Collapse
|
6
|
Perea J, García JL, Corchete L, Lumbreras E, Arriba M, Rueda D, Tapial S, Pérez J, Vieiro V, Rodríguez Y, Brandáriz L, García-Arranz M, García-Olmo D, Goel A, Urioste M, Sarmiento RG. Redefining synchronous colorectal cancers based on tumor clonality. Int J Cancer 2018; 144:1596-1608. [PMID: 30151896 DOI: 10.1002/ijc.31761] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 06/14/2018] [Accepted: 07/13/2018] [Indexed: 12/19/2022]
Abstract
To analyze the possible clonal origin of a part of Synchronous colorectal cancer (SCRC), we studied 104 paired-SCRCs from 52 consecutive patients without hereditary forms of CRC. We used a Single-Nucleotide Polymorphism array to characterize the genomic profiles, and subsequently used a statistical application to define them according to clonality within the same individual. We categorized the ensuing groups according to colonic location to identify differential phenotypes. The SCRC Monoclonal group (M) (19 cases) was divided into Monosegmental (MM) and Pancolonic (MP) groups. The SCRC Polyclonal group (P) (33 cases) was also divided into Monosegmental (PM) and Pancolonic (PP), the first exhibiting preference for left colon. The MM group showed a high rate of mucinous tumors, the lowest mean-number of tumors and associated-polyps, and the worst prognosis. The MP group included the largest mean-number of associated-polyps, best prognosis and familial cancer component. The PM group seemed to be a "frontier" group. Finally, the PP group also exhibited a mucin component, the highest mean-number of tumors (4.6) compared with the mean-number of polyps (7.7), poor prognosis and sporadic cases. Most relevant differential genomic regions within M groups were gains on 1q24 and 8q24, and deletions on 1p21 and 1p23 for MM, while within P were the gains on 7q36 and deletions on 1p36 for PM. The statistical application employed seems to define clonality more accurately in SCRC -more likely to be polyclonal in origin-, and together with the tumor locations, helped us to configure a classification with prognostic and clinical value.
Collapse
Affiliation(s)
- José Perea
- Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.,Health Research Institute Fundación Jiménez Díaz, Madrid, Spain
| | - Juan L García
- Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.,Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain
| | - Luis Corchete
- Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.,Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain
| | - Eva Lumbreras
- Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.,Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain
| | - María Arriba
- Biochemistry Department, Gregorio Marañón University Hospital, Madrid, Spain
| | - Daniel Rueda
- Centre for Biomedical Research of the 12 de Octubre University Hospital, Madrid, Spain.,Molecular Biology Laboratory, 12 de Octubre University Hospital, Madrid, Spain
| | - Sandra Tapial
- Centre for Biomedical Research of the 12 de Octubre University Hospital, Madrid, Spain
| | - Jessica Pérez
- Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.,Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain
| | - Victoria Vieiro
- Surgery Department, 12 de Octubre University Hospital, Madrid, Spain
| | - Yolanda Rodríguez
- Department of Pathology, 12 de Octubre University Hospital, Madrid, Spain
| | - Lorena Brandáriz
- Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.,Health Research Institute Fundación Jiménez Díaz, Madrid, Spain
| | | | - Damián García-Olmo
- Surgery Department, Fundación Jiménez Díaz University Hospital, Madrid, Spain.,Health Research Institute Fundación Jiménez Díaz, Madrid, Spain
| | - Ajay Goel
- Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX
| | - Miguel Urioste
- Familial Cancer Clinical Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.,Center for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain
| | - Rogelio González Sarmiento
- Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca-USAL-CSIC, Salamanca, Spain.,Institute of Molecular and Cellular Biology of Cancer (IBMCC), University of Salamanca-CSIC, Salamanca, Spain
| |
Collapse
|
7
|
Arriba M, Sánchez R, Rueda D, Gómez L, García JL, Rodríguez Y, Pajares JA, Pérez J, Urioste M, Sarmiento RG, Perea J. Toward a Molecular Classification of Synchronous Colorectal Cancer: Clinical and Molecular Characterization. Clin Colorectal Cancer 2017; 16:31-37. [DOI: 10.1016/j.clcc.2016.07.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2016] [Revised: 07/22/2016] [Accepted: 07/28/2016] [Indexed: 02/07/2023]
|
8
|
López Valverde G, Garcia Martin E, Larrosa Povés JM, Polo Llorens V, Fernández Mateos J, Pablo Júlvez LE, Sarmiento RG. Correction: Study of Association between Pre-Senile Cataracts and the Polymorphisms rs2228000 in XPC and rs1042522 in p53 in Spanish Population. PLoS One 2017; 12:e0171395. [PMID: 28125715 PMCID: PMC5268642 DOI: 10.1371/journal.pone.0171395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
|
9
|
Usategui-Martín R, Calero-Paniagua I, García-Aparicio J, Corral-Gudino L, Del Pino Montes J, González Sarmiento R. VAV3 Gene Polymorphism Is Associated with Paget's Disease of Bone. Genet Test Mol Biomarkers 2016; 20:335-7. [PMID: 27172236 DOI: 10.1089/gtmb.2015.0292] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND AND AIMS Paget's disease of bone (PDB) is a focal bone disorder affecting the skeleton segmentally. The disease affects osteoclasts which increase in size, number, and activity. One of the etiopathogenic hypotheses is that the disease is genetic. It has been reported that Rho GEF Vav3 is an essential factor in the regulation of osteoclast function, and alteration of the VAV3 gene could influence the development of the disease. The aim of our study was to perform an association study between variants of the VAV3 gene and the risk of developing Paget's disease of bone. PATIENTS AND METHODS The genotypic and allelic distribution of the VAV3 c.892A>T/p.T298S (rs7528153) polymorphism was compared between a cohort of 238 Spanish subjects with PDB and a cohort of 253 healthy subjects. RESULTS Our results indicated that individuals carrying the VAV3 rs7528153 TT genotype were at a significantly increased risk of developing PDB (p < 0.001, odds ratio [OR] = 3.15, 95% confidence interval [95% CI] = 1.77-5.61). CONCLUSIONS These results suggest that inheriting the VAV3 rs7528153 polymorphism is a likely susceptibility factor for developing Paget's disease of bone.
Collapse
Affiliation(s)
- Ricardo Usategui-Martín
- 1 Unidad de Medicina Molecular, Departamento de Medicina, Universidad de Salamanca , Salamanca, Spain .,2 Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC , Salamanca, Spain
| | - Ismael Calero-Paniagua
- 2 Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC , Salamanca, Spain .,3 Servicio de Reumatología, Hospital Universitario de Salamanca , Salamanca, Spain
| | - Judith García-Aparicio
- 2 Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC , Salamanca, Spain .,4 Servicio de Medicina Interna, Hospital Universitario de Salamanca , Salamanca, Spain
| | - Luis Corral-Gudino
- 4 Servicio de Medicina Interna, Hospital Universitario de Salamanca , Salamanca, Spain
| | - Javier Del Pino Montes
- 2 Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC , Salamanca, Spain .,3 Servicio de Reumatología, Hospital Universitario de Salamanca , Salamanca, Spain
| | - Rogelio González Sarmiento
- 1 Unidad de Medicina Molecular, Departamento de Medicina, Universidad de Salamanca , Salamanca, Spain .,2 Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca-USAL-CSIC , Salamanca, Spain .,5 Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Universidad de Salamanca-CSIC , Salamanca, Spain
| |
Collapse
|
10
|
Usategui-Martín R, García-Aparicio J, Corral-Gudino L, Calero-Paniagua I, Del Pino-Montes J, González Sarmiento R. Polymorphisms in autophagy genes are associated with paget disease of bone. PLoS One 2015; 10:e0128984. [PMID: 26030385 PMCID: PMC4452234 DOI: 10.1371/journal.pone.0128984] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2015] [Accepted: 05/04/2015] [Indexed: 11/19/2022] Open
Abstract
Paget disease of bone (PDB) is a focal bone disorder affecting the skeleton segmentally. The main alteration resides in osteoclasts that increase in size, number and activity. Many osteoclasts have cytoplasmic inclusions that have been associated with protein aggregates, increasing the evidences of a possible deregulation of autophagy in the development of the PDB. Autophagy starts with encapsulation of the target into a double-membrane-bound structure called an “autophagosome.” It has been reported that at least 18 ATG genes (autophagy-related genes) are involved in autophagosome formation. We have studied the distribution of genotypes of the ATG2B rs3759601, ATG16L1 rs2241880, ATG10 rs1864183 and ATG5 rs2245214 polymorphisms in a Spanish cohort of subjects with PDB and compared with healthy subjects. Our results show that being a carrier of the C allele of the ATG16L1 rs2241880 and the G allele of ATG5 rs2245214 polymorphisms were associated with an increased risk of developing PDB, whereas being a carrier of the T allele of ATG10 rs1864183 polymorphism decreased the risk of suffering the disease in our series. This is the first report that shows an association between autophagy and Paget Disease of Bone and requires further confirmation in other series.
Collapse
Affiliation(s)
- Ricardo Usategui-Martín
- Unidad de Medicina Molecular-IBSAL, Departamento de Medicina, Universidad de Salamanca-Hospital Universitario de Salamanca-CSIC, Salamanca, España
| | - Judith García-Aparicio
- Servicio de Medicina interna-IBSAL, Hospital Universitario de Salamanca Universidad de Salamanca CSIC, Salamanca, España
| | - Luis Corral-Gudino
- Servicio de Medicina interna-IBSAL, Hospital Universitario de Salamanca Universidad de Salamanca CSIC, Salamanca, España
| | - Ismael Calero-Paniagua
- Servicio de Reumatología-IBSAL, Hospital Universitario de Salamanca-Universidad de Salamanca-CSIC, Salamanca, España
| | - Javier Del Pino-Montes
- Servicio de Reumatología-IBSAL, Hospital Universitario de Salamanca-Universidad de Salamanca-CSIC, Salamanca, España
| | - Rogelio González Sarmiento
- Unidad de Medicina Molecular-IBSAL, Departamento de Medicina, Universidad de Salamanca-Hospital Universitario de Salamanca-CSIC, Salamanca, España
- Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Universidad de Salamanca-CSIC, Salamanca, España
- * E-mail:
| |
Collapse
|
11
|
Ozyurt K, Subasioglu A, Ozturk P, Inci R, Ozkan F, Bueno E, Cañueto J, González Sarmiento R. Emopamil binding protein mutation in conradi-hünermann-happle syndrome representing plaque-type psoriasis. Indian J Dermatol 2015; 60:216. [PMID: 25814754 PMCID: PMC4372958 DOI: 10.4103/0019-5154.152570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Conradi-Hünermann-Happle syndrome (CDPX2, OMIM 302960) is an inherited X-linked dominant variant of chondrodysplasia punctata which primarily affects the skin, bones, and eyes. CDPX2 patients display skin defects, including ichthyotic lesions, follicular atrophoderma, cicatricial alopecia, and less frequently ichthyosiform erythroderma, cataracts, and skeletal abnormalities consisting of short stature, asymmetric shortening of the limbs, epiphyseal stippling, and craniofacial defects. CDPX2 results from mutations in emopamil binding protein (EBP) gene. The aim of our study is to identify EBP mutation in a unique case of Conradi-Hünermann-Happle syndrome with rare psoriasiform lesions.
Collapse
Affiliation(s)
- Kemal Ozyurt
- Department of Dermatology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey
| | - Asli Subasioglu
- Department of Medical Genetics, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey
| | - Perihan Ozturk
- Department of Dermatology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey
| | - Rahime Inci
- Department of Dermatology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey
| | - Fuat Ozkan
- Department of Radiology, Sutcu Imam University, School of Medicine, Kahramanmaras, Turkey
| | - Elena Bueno
- Department of Molecular Medicine, University of Salamanca, Salamanca, Spain
| | - Javier Cañueto
- Department of Dermatology, University Hospital of Salamanca, Salamanca, Spain
| | | |
Collapse
|
12
|
Sklate RT, Olcese MC, Maccallini GC, Sarmiento RG, Targovnik HM, Rivolta CM. Novel mutation p.A64D in the Serpina7 gene as a cause of partial thyroxine-binding globulin deficiency associated with increases affinity in transthyretin by a known p.A109T mutation in the TTR gene. Horm Metab Res 2014; 46:100-8. [PMID: 24356794 DOI: 10.1055/s-0033-1358741] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Partial thyroxine-binding globulin deficiency (TBG-PD) is an endocrine defect with a prevalence of 1:4 000 in newborns. Due to the presence of a single TBG gene on the X chromosome, most familial TBG defects follow an X-linked inheritance pattern. Abnormal T4 binding to T4-binding prealbumin (TTR) is a rare cause of euthyroid hyperthyroxinemia, which is transmitted by autosomal dominant inheritance. The purpose of the present study was to identify and characterize new mutations in the Serpina7 and TTR genes in a complete family with typical TBG-PD. All patients underwent clinical and biochemical evaluation. Sequencing of DNA, population screening by (SSCP) analysis, and bioinformatics studies were performed. Molecular studies revealed a novel p.A64D mutation in the exon 1 of Serpina7 gene associated with the previously reported p.A109T mutation in the exon 4 of TTR gene. To our knowledge, this is the first report of a patient with a TBG-PD by a mutation in Serpina7 that was coincident with a mutation in TTR gene that increased affinity of TTR for T4. This work contributes to elucidate the molecular basis of the defects of thyroid hormone transport in serum and the improvement of the diagnosis avoiding unnecessary therapy.
Collapse
Affiliation(s)
- R T Sklate
- Servicio de Endocrinología, Departamento de Medicina, Hospital General de Agudos "Dr. Enrique Tornú", C1427ARN Buenos Aires, Argentina
| | - M C Olcese
- Laboratorio de Genética y Biología Molecular, Instituto de Inmunología, Genética y Metabolismo (INIGEM, CONICET-UBA), Hospital de Clínicas "José de San -Martín", C1120AAR Buenos Aires, Argentina
| | - G C Maccallini
- División Laboratorio, Hospital General de Agudos "Dr. Carlos G. Durand", C1405DCS Buenos Aires, Argentina
| | - R G Sarmiento
- Unidad de Medicina Molecular-Departamento de Medicina, IBMCC and IBSAL. Universidad de Salamanca-CSIC, Salamanca, España
| | - H M Targovnik
- Laboratorio de Genética y Biología Molecular, Instituto de Inmunología, Genética y Metabolismo (INIGEM, CONICET-UBA), Hospital de Clínicas "José de San -Martín", C1120AAR Buenos Aires, Argentina
| | - C M Rivolta
- Laboratorio de Genética y Biología Molecular, Instituto de Inmunología, Genética y Metabolismo (INIGEM, CONICET-UBA), Hospital de Clínicas "José de San -Martín", C1120AAR Buenos Aires, Argentina
| |
Collapse
|
13
|
Núñez Lozano M, González Sarmiento R. [Genetic and molecular bases of paragangliomas]. Acta Otorrinolaringol Esp 2009; 60 Suppl 1:24-28. [PMID: 19245772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Paragangliomas and pheochromocytomas are neuroendocrine tumors arising in the extraadrenal and adrenal medulla, respectively. These tumors appear in certain familial syndromes, such as multiple endocrine neoplasia types 1 and 2, Von Hippel Lindau disease, neurofibromatosis type 1 and familial paraganglioma syndromes. The latter syndromes show a strong association with germline mutations of succinate dehydrogenase subunits, such as SDHB, SDHC and SDHD. This enzyme complex is related to tumorigenesis through mechanisms involved in cell proliferation, apoptosis, and alterations in oxygen sensing function, although none of these factors has been clearly identified as a cause of tumoral development. In the last few years, several studies have been performed of these genes in relation to correct diagnosis of paraganglioma and pheochromocytoma, as well as determination of germline mutations in familial and sporadic cases and its utility in genetic counselling in these patients.
Collapse
Affiliation(s)
- Mercedes Núñez Lozano
- Unidad de Medicina Molecular, Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
| | | |
Collapse
|
14
|
Mata IF, Alvarez V, García-Moreira V, Guisasola LM, Ribacoba R, Salvador C, Blázquez M, Sarmiento RG, Lahoz CH, Menes BB, García EC. Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. Neurosci Lett 2002; 329:149-52. [PMID: 12165399 DOI: 10.1016/s0304-3940(02)00619-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Mutations in the PARKIN gene have been identified in families with recessively inherited Parkinson disease (PD). Common DNA-polymorphisms at the PARKIN gene could contribute to the risk for PD in the general population. Here we searched for DNA-polymorphisms in the PARKIN promoter. We found two single nucleotide polymorphisms (-324 A/G and -797 A/G). In order to analyse the association of PD with these and two previously described polymorphisms (1281 G/A, Asp394Asn, and 601 G/A, Ser167Asn) we genotyped 105 patients and 150 healthy controls. Allele and genotype frequencies for the four polymorphisms did not differ between patients and controls, or between patients with an early-onset (< or =40 years; n = 20) and a late-onset (>40 years; n = 85). According to our data, the genetic variation at the PARKIN gene (including promoter polymorphisms) did not contribute to the risk of developing PD in the general population.
Collapse
Affiliation(s)
- Ignacio F Mata
- Genética Molecular-Instituto Investigación Nefrológica (IRSIN), Hospital Central de Asturias, 33006 Oviedo, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Trejo-Becerril C, Sarmiento RG, Abad MM, Ichaso N, Delgado R, Cruz JJ, Dueñas-González A. Immunohistochemical expression of p53 in breast carcinoma is associated with the intron 1 BglII polymorphism of the p53 gene. Mutat Res 2000; 452:231-6. [PMID: 11024482 DOI: 10.1016/s0027-5107(00)00071-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Breast carcinoma is a public health problem worldwide. It is known that both genetic and environmental factors are important for breast carcinogenesis and that structural and/or functional alterations at p53 gene are commonly observed in breast tumors. In addition, polymorphisms of several genes in either their coding or non-coding sequences have been found related to cancer risk and/or clinicopathological characteristics of tumors. In this study we have evaluated the intron 1 BglII polymorphism of the p53 gene with a PCR-based approach in 117 cases of breast cancer and 102 healthy women and its association with the immunohistochemical expression of p53 in the tumors. The results showed that the presence of the polymorphism (allele 2) is highly associated with the tumor expression of p53 (p<0.0001) and that there is a trend for increased frequency of allele 2 in cases than in controls (p=0.2376). These data suggest that the germ-line variation in the intron 1 of the p53 gene could produce functional or structural changes of the protein that is reflected by its abnormal expression.
Collapse
Affiliation(s)
- C Trejo-Becerril
- Basic Research, Instituto Nacional de Cancerologia, Mexico City, Mexico
| | | | | | | | | | | | | |
Collapse
|
16
|
García JE, López AM, de Cabo MR, Rodríguez FM, Losada JP, Sarmiento RG, López AJ, Arellano JL. Cyclosporin A decreases human macrophage interleukin-6 synthesis at post-transcriptional level. Mediators Inflamm 1999; 8:253-9. [PMID: 10704080 PMCID: PMC1781800 DOI: 10.1080/09629359990423] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
In addition to its well-established effect on T cells, cyclosporin A (CsA) also inhibits inflammatory cytokine production by macrophages. However, little is known about the mechanism of action of CsA on macrophage cytokine production. We measured the effect of CsA on basal and phorbol-myristate-acetate (PMA)-stimulated production of interleukin-6 using the human monocyte cell line U937 differentiated with dimethylsulfoxide (DMSO). Interleukin-6 levels were measured in supernatant and cell lysates using specific enzyme-linked immunosorbent assays. We found that CsA decreases not only IL-6 release but also cytokine synthesis. The concentration of CsA used did not affect either cell viability or proliferation. Three possibilities may be advanced to explain the CsA-due decrease in IL-6 production by macrophages: (a) inhibition of the synthesis of an early common regulatory protein, (b) inhibition of cytokine gene transcription, or (c) modulation of post-transcriptional events. The first possibility was tested by measuring the effect of cycloheximide on the experimental system during the first 3 hours of culture. Although cycloheximide decreased total cytokine synthesis, the pattern of cytokine modulation by CsA persisted. These data suggest that CsA-mediated macrophage cytokine inhibition is not mediated by an early common regulatory protein. To further explore the inhibition mechanism, we measured IL-6 mRNA levels by Northern blot. IL-6 mRNA levels were unaffected by CsA both in resting and PMA-stimulated cells. We conclude that in human macrophages CsA diminishes IL-6 production at post-transcriptional level.
Collapse
Affiliation(s)
- J E García
- Area de Medicina, Fundación Hospital de Alcorcón, Madrid, Spain.
| | | | | | | | | | | | | | | |
Collapse
|